Elan’s Board Unanimously Rejects Royalty Pharma’s Revised OfferMani
Elan Corporation, plc (NYSE:ELN) today announced that its board of directors has rejected a revised bid from privately held investment firm Royalty Pharma.
Irish biotechnology firm Elan Corporation, plc (NYSE:ELN) said its board has rejected the offer from Royalty Pharma, through its subsidiary Echo Pharma Acquisition Ltd, to acquire all of the shares of Elan Corporation, plc (NYSE:ELN) for $13.00 plus up to an additional $2.50 per share in contingent voting rights (CVR).
What . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click Chat.